At the 7th China International Import Expo (CIIE), themed "New Era, Shared Future", representatives from 152 countries, regions, and organizations gathered for national and corporate exhibitions. On 8 November, Switzerland Global Enterprise (S-GE) visited the China Association of In Vitro Diagnostics (CAIVD) to explore future collaboration and growth opportunities in the field of in vitro diagnostics (IVD).

BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory at Uruguay's Parque de las Ciencias free trade zone. This facility is poised to become a regional hub, advancing preventive medicine across Latin America and utilizing advanced technology to facilitate early disease diagnosis.

According to the Global Burden of Disease Study 2019, the number of people diagnosed with dementia is expected to almost triple by 2050.

With over 40 years of development, China's in vitro diagnostic (IVD) industry has made significant strides, presenting a comprehensive range of products that boast improving quality and surging export demands. The internationalization of IVD products, especially concerning human health, emerges as a pivotal strategy of companies for manufacturing, development, and future growth.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. ( “Mindray”) has agreed to acquire 75% equity interest in DiaSys Diagnostic Systems GmbH (“DiaSys”) from Gorka Holding GmbH, through Mindray Medical Netherlands B.V. (“Mindray Netherlands”), a wholly-owned subsidiary of Mindray’s wholly-owned subsidiary MR Global (HK) Limited, for an all-cash preliminary purchase price of approx. €115 million.

Recently, Wondfo Bio and Merck, a leading global technology company, held a globalization cooperation seminar and unanimously decided to deepen the cooperation on the basis of the pilot cooperation in the previous period, expanding the project coverage area and the population, and joining hands to enhance the accessibility of the diagnosis and treatment of thyroid diseases at the grassroots level in the world.

According to Kalorama Information, the U.S. IVD market reached $53 billion in 2022, or approximately 40% to 45% of the global market. Projected growth is 2.4% annually on average through 2027.

2021 ranking features 143 Chinese companies, 122 U.S. companies, and 53 Japanese companies. 6 in vitro diagnostic companies on the list.